Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Tumor Immunotherapy

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.

Metastasis

Metastasis

Metastasis is the spread of cancer cells from the original site to distant locations in the body. Cancer cells can spread via blood vessels (hematogenous) as well as lymph vessels in the body.
Epithelial-to-Mesenchymal Transition
The epithelial-to-mesenchymal transition or EMT is a developmental process commonly observed in wound healing, embryogenesis, and cancer metastasis. EMT is induced by transforming growth factor-beta (TGF-β) or receptor tyrosine kinase (RTK) ligands, which further...

The Tumor Microenvironment

The Tumor Microenvironment

Every normal cell or tissue is embedded in a complex local environment called stroma, consisting of different cell types, a basal membrane, and blood vessels. As normal cells mutate and develop into cancer cells, their local environment also changes to allow cancer progression. The tumor microenvironment (TME) consists of a complex cellular matrix of stromal cells and the developing tumor. The cross-talk between cancer cells and surrounding stromal cells is critical to disrupt normal tissue...

The Tumor Microenvironment

The Tumor Microenvironment

Every normal cell or tissue is embedded in a complex local environment called stroma, consisting of different cell types, a basal membrane, and blood vessels. As normal cells mutate and develop into cancer cells, their local environment also changes to allow cancer progression. The tumor microenvironment (TME) consists of a complex cellular matrix of stromal cells and the developing tumor. The cross-talk between cancer cells and surrounding stromal cells is critical to disrupt normal tissue...

Cancer-Critical Genes II: Tumor Suppressor Genes

Cancer-Critical Genes II: Tumor Suppressor Genes

Genes usually encode proteins necessary for the proper functioning of a healthy cell. Mutations can often cause changes to the gene expression pattern, thereby altering the phenotype.
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Evaluation of safety, efficacy, and guideline compliance in home-based red blood cell transfusions: An 8.5-year retrospective study in suburban Tokyo.

Transfusion medicine (Oxford, England)·2026

Same author

Revisiting the Real-World Prognosis of Intensive Chemotherapy in Elderly Acute Myeloid Leukemia Patients: A Retrospective Analysis from Tokyo.

Indian journal of hematology & blood transfusion : an official journal of Indian Society of Hematology and Blood Transfusion·2025

Same author

Engraftment outcome of patients with anti-HLA antibodies in HLA-mismatched peripheral blood stem cell transplantation.

International journal of hematology·2025

Same author

Dexamethasone-induced hiccups in patients with COVID-19.

International journal of clinical pharmacology and therapeutics·2023

Same author

[Multiple extramedullary plasmacytomas responding to a reduced dose of carfilzomib following drug-induced thrombotic microangiopathy].

[Rinsho ketsueki] The Japanese journal of clinical hematology·2023

Same author

Myeloid leukemoid reaction after initial azacitidine therapy for chronic myelomonocytic leukemia.

International journal of hematology·2022

Search research articles

Related Experiment Video

Updated: Jun 12, 2026

Neutrophil Extracellular Traps Generated by Low Density Neutrophils Obtained from Peritoneal Lavage Fluid Mediate Tumor Cell Growth and Attachment

Neutrophil Extracellular Traps Generated by Low Density Neutrophils Obtained from Peritoneal Lavage Fluid Mediate Tumor Cell Growth and Attachment

Published on: August 3, 2018

[Tumor lysis syndrome].

Takeshi Hagino¹

¹Division of Oncology/Hematology, Department of Internal Medicine, The Jikei University School of Medicine.

Gan to Kagaku Ryoho. Cancer & Chemotherapy

|June 23, 2010

Summary

This summary is machine-generated.

Tumor lysis syndrome (TLS) is a severe chemotherapy complication. Early diagnosis and aggressive management, including rasburicase, significantly reduce TLS risks and improve patient outcomes.

More Related Videos

An Immunocompetent Murine Model for Laser Interstitial Thermal Therapy of Glioblastoma

An Immunocompetent Murine Model for Laser Interstitial Thermal Therapy of Glioblastoma

Published on: November 15, 2024

Generation of Microtumors Using 3D Human Biogel Culture System and Patient-derived Glioblastoma Cells for Kinomic Profiling and Drug Response Testing

Generation of Microtumors Using 3D Human Biogel Culture System and Patient-derived Glioblastoma Cells for Kinomic Profiling and Drug Response Testing

Published on: June 9, 2016

Related Experiment Videos

Last Updated: Jun 12, 2026

Neutrophil Extracellular Traps Generated by Low Density Neutrophils Obtained from Peritoneal Lavage Fluid Mediate Tumor Cell Growth and Attachment

Neutrophil Extracellular Traps Generated by Low Density Neutrophils Obtained from Peritoneal Lavage Fluid Mediate Tumor Cell Growth and Attachment

Published on: August 3, 2018

An Immunocompetent Murine Model for Laser Interstitial Thermal Therapy of Glioblastoma

An Immunocompetent Murine Model for Laser Interstitial Thermal Therapy of Glioblastoma

Published on: November 15, 2024

Generation of Microtumors Using 3D Human Biogel Culture System and Patient-derived Glioblastoma Cells for Kinomic Profiling and Drug Response Testing

Generation of Microtumors Using 3D Human Biogel Culture System and Patient-derived Glioblastoma Cells for Kinomic Profiling and Drug Response Testing

Published on: June 9, 2016

Area of Science:

Oncology
Nephrology
Internal Medicine

Context:

Tumor lysis syndrome (TLS) is a critical oncologic emergency arising from rapid cancer cell breakdown during chemotherapy.
TLS presents with distinct metabolic derangements: hyperuricemia, hyperkalemia, hyperphosphatemia, and hypocalcemia, potentially leading to acute kidney injury and acidosis.

Purpose:

To outline the pathophysiology, predisposing factors, and clinical characteristics of tumor lysis syndrome.
To detail the essential management strategies for TLS, emphasizing prevention, early diagnosis, and therapeutic interventions.

Summary:

Predisposing factors for TLS include high tumor burden, rapid cell turnover, chemotherapy sensitivity, and pre-existing renal dysfunction.
Management involves aggressive hydration, urinary alkalization, electrolyte correction, uric acid inhibition (e.g., allopurinol), and uric acid breakdown (rasburicase).
Rasburicase (recombinant urate oxidase) is highlighted for its significant role in reducing TLS morbidity and mortality.

Impact:

Proactive management, including risk assessment before chemotherapy, is crucial for preventing TLS.
Early recognition and prompt, aggressive treatment are vital for mitigating severe complications and improving survival rates in cancer patients.
Understanding TLS pathophysiology and management optimizes patient care during anti-cancer therapy.